内容紹介
A Case of Unresected Gastric Cancer That Maintained Long Tumor Dormancy by Use of Paclitaxel+S-1 Combination Therapy
Summary
Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy. A 58-year-old woman was admitted to the hospital for peritoneal dissemination of unresectable gastric cancer. The patient further showed ileus with peritoneal dissemination in computed tomography(CT), and we performed resection of the intestine to release the stenosis. In addition, combination chemotherapy using paclitaxel(60 mg/m2, weekly)and S-1(80 mg/m2, every 2 weeks)was started after the operation. The patient was discharged from the hospital 73 days after the operation, and we continued combination chemotherapy as an outpatient over the following 3 years without serious side effects. Furthermore, tumor makers for gastric cancer were stable, although we could not examine tumor size since the patient rejected examinations such as CT. After 3 years, the patient was admitted to the hospital with cholecystitis, and we were able to evaluate the benefit of the chemotherapy against gastric cancer. The tumor size clearly remained unchanged compared to previous measurements, suggesting that the tumor maintained dormancy in this case.
要旨
今回われわれは,腹膜播種を伴った高度進行胃癌に対しpaclitaxel+S-1併用療法を行い,3年以上tumor dormancyを維持することができた1例を経験したので報告する。症例は58歳,女性。3型進行胃癌と多発腹膜播種による腸閉塞を認め入院となった。2009年1月,腸閉塞の解除目的に小腸部分切除術を施行した。原発巣は根治不能であった。術後7日目に残存胃癌に対しpaclitaxel+S-1併用療法(paclitaxel 60 mg/m2 3週投与1週休薬,S-1 80 mg/m2 day 2週投与1週休薬)を開始した。Grade 1以上の副作用はなく,その後3年間同併用療法を行うことができた。その間,腫瘍マーカーの上昇はなかった。また,自覚症状はなく通常の社会生活を過ごし,tumor dormancyの状態を継続している。
目次
Summary
Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy. A 58-year-old woman was admitted to the hospital for peritoneal dissemination of unresectable gastric cancer. The patient further showed ileus with peritoneal dissemination in computed tomography(CT), and we performed resection of the intestine to release the stenosis. In addition, combination chemotherapy using paclitaxel(60 mg/m2, weekly)and S-1(80 mg/m2, every 2 weeks)was started after the operation. The patient was discharged from the hospital 73 days after the operation, and we continued combination chemotherapy as an outpatient over the following 3 years without serious side effects. Furthermore, tumor makers for gastric cancer were stable, although we could not examine tumor size since the patient rejected examinations such as CT. After 3 years, the patient was admitted to the hospital with cholecystitis, and we were able to evaluate the benefit of the chemotherapy against gastric cancer. The tumor size clearly remained unchanged compared to previous measurements, suggesting that the tumor maintained dormancy in this case.
要旨
今回われわれは,腹膜播種を伴った高度進行胃癌に対しpaclitaxel+S-1併用療法を行い,3年以上tumor dormancyを維持することができた1例を経験したので報告する。症例は58歳,女性。3型進行胃癌と多発腹膜播種による腸閉塞を認め入院となった。2009年1月,腸閉塞の解除目的に小腸部分切除術を施行した。原発巣は根治不能であった。術後7日目に残存胃癌に対しpaclitaxel+S-1併用療法(paclitaxel 60 mg/m2 3週投与1週休薬,S-1 80 mg/m2 day 2週投与1週休薬)を開始した。Grade 1以上の副作用はなく,その後3年間同併用療法を行うことができた。その間,腫瘍マーカーの上昇はなかった。また,自覚症状はなく通常の社会生活を過ごし,tumor dormancyの状態を継続している。